HESA-A is an herbal-marine compound which improves the quality of life of end-stage cancer patients. The aim of the present study was to evaluate the possible protective effect of HESA-A against IR-induced genotoxicity and apoptosis in rat bone marrow. Rats were given HESA-A orally at doses of 150 and 300 mg/kg body weight for seven consecutive days. On the seventh day, the rats were irradiated with 4 Gy X-rays at 1 h after the last oral administration. The micronucleus assay, reactive oxygen species (ROS) level analysis, hematological analysis and flow cytometry were used to assess radiation antagonistic potential of HESA-A. Administration of 150 and 300 mg/kg of HESA-A to irradiated rats significantly reduced the frequencies of micronucleated polychromatic erythrocytes (MnPCEs) and micronucleated normochromatic erythrocytes (MnNCEs), and also increased PCE/(PCE + NCE) ratio in bone marrow cells. Moreover, pretreatment of irradiated rats with HESA-A (150 and 300 mg/kg) significantly decreased ROS level and apoptosis in bone marrow cells, and also increased white blood cells count in peripheral blood. For the first time in this study, it was observed that HESA-A can have protective effects against radiation-induced genotoxicity and apoptosis in bone marrow cells. Therefore, HESA-A can be considered as a candidate for future studies to reduce the side effects induced by radiotherapy in cancer patients.

中文翻译：

---

HESA-A：一种保护大鼠免受骨髓细胞电离辐射致遗传毒性和细胞凋亡的保护剂：一种新型草药-海洋化合物。

HESA-A是一种草药海洋化合物，可改善晚期癌症患者的生活质量。本研究的目的是评估HESA-A对IR诱导的大鼠骨髓遗传毒性和细胞凋亡的保护作用。连续7天给大鼠口服150和300 mg / kg体重的HESA-A。在第7天，在最后一次口服给药后1小时，用4 Gy X射线照射大鼠。用微核试验，活性氧（ROS）水平分析，血液学分析和流式细胞术评估HESA-A的放射拮抗潜力。向受辐照的大鼠施用150和300 mg / kg的HESA-A可以显着降低微核多色红细胞（MnPCE）和微核正色红细胞（MnNCE）的频率，并且还增加了骨髓细胞中PCE /（PCE + NCE）的比率。此外，用HESA-A（150和300 mg / kg）对辐照大鼠进行预处理可显着降低骨髓细胞的ROS水平和细胞凋亡，并且还可增加外周血中的白细胞数量。首次在这项研究中观察到，HESA-A对辐射诱导的骨髓细胞遗传毒性和细胞凋亡具有保护作用。因此，HESA-A可以被认为是减少癌症患者放射治疗引起的副作用的未来研究的候选者。首次在这项研究中观察到，HESA-A对辐射诱导的骨髓细胞遗传毒性和细胞凋亡具有保护作用。因此，HESA-A可以被认为是减少癌症患者放射治疗引起的副作用的未来研究的候选者。首次在这项研究中观察到，HESA-A对辐射诱导的骨髓细胞遗传毒性和细胞凋亡具有保护作用。因此，HESA-A可以被认为是减少癌症患者放射治疗引起的副作用的未来研究的候选者。